Stock Price Quote

VAISHALI PHARMA LTD.

NSE : VAISHALIBSE : ISIN CODE : INE972X01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE0.000 (0 %)
PREV CLOSE ( ) NA
OPEN PRICE ( ) 0.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 0
TODAY'S LOW / HIGH ( )0.00 0.00
52 WK LOW / HIGH ( )0 0
NSE151.91-1.01 (-0.66 %)
PREV CLOSE( ) 152.92
OPEN PRICE ( ) 153.50
BID PRICE (QTY) 151.92 (46)
OFFER PRICE (QTY) 152.31 (26)
VOLUME 6099
TODAY'S LOW / HIGH( ) 150.21 153.50
52 WK LOW / HIGH ( )114.85 203.6
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 25-04 2008
Management Info
Atul Vasani - Chairman Atul Vasani - Managing Director
Registered Office

Address 706 To 709, 7th Floor, Aravali Busines Center,R. C. Patel Road, Off Sodawala Lane,Borivali (West),
Mumbai,
Maharashtra-400092

Phone 022 42171819

Email investor@vaishalipharma.com / cs@vaishalipharma.com

Website www.vaishalipharma.com

Registrars Details
Bigshare Services Pvt Ltd
Office No S6-2, 6th Floor, Pinnacle Business Park,Next to Ahura Centre, Mahakali Caves Road,Andheri (E),Mumbai
Listing : NSE

NEWS

14May Substantial Acquisition of Shares
Vaishali Pharma Limited??has Submitted to the Exchange a copy of Disclos..
13May Allotment of Equity Shares
VAISHALI PHARMA LIMITED has informed the Exchange regarding Allotment of..
13May Outcome of Board Meeting
Vaishali Pharma Limited has informed the Exchange regarding Board meeti..
06Apr General Announcement
Vaishali Pharma Limited has informed the Exchange about Certificate unde..
30Mar Closure of Trading Window
Vaishali Pharma Limited has informed the Exchange regarding the Trading..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit-46.847.18999999999992
Gross Profit -64.18 9.25999999999992
Operating Profit -58.7631.7099999999999
Net Sales 323.96862.8

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Sanofi India (BSE)
peergroup  6838.70 (5.00%)
M.Cap ( in Cr)14999.96
NGL Fine-Chem (BSE)
peergroup  2416.40 (3.48%)
M.Cap ( in Cr)1442.69
Astrazeneca Pharma I (BSE)
peergroup  6421.35 (1.11%)
M.Cap ( in Cr)15877.38
Glaxosmithkline Phar (BSE)
peergroup  2752.45 (1.98%)
M.Cap ( in Cr)45724.38
Strides Pharma Scien (BSE)
peergroup  984.50 (4.50%)
M.Cap ( in Cr)8659.47

Shareholding Pattern

NON-INSTITUTION 73.68%
PROMOTERS 26.32%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Vaishali Pharma Ltd.

Vaishali Pharma Ltd. was incorporated in the year 2008. Its today's share price is 0. Its current market capitalisation stands at Rs 176.53 Cr. In the latest quarter, company has reported Gross Sales of Rs. 696.63 Cr and Total Income of Rs.718.92 Cr. The company's management includes Manish Bhagwandas Ved, Ashvin Jamnadas Ganatra, Vishwa Mekhia, Pratik Jakhelia, Dewansh Vasani, Jagruti Vasani, Atul Vasani, Atul Vasani.

It is listed on the BSE with a BSE Code of  , NSE with an NSE Symbol of VAISHALI and ISIN of INE972X01014. It's Registered office is at 706 To 709, 7th Floor, Aravali Busines Center,R. C. Patel Road, Off Sodawala Lane,Borivali (West)Mumbai-400092, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Raman S Shah & Associates, S K Bobra & Co., SK Bobra & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.